PRQR - ProQR Therapeutics N.V.
7.97 0.00 (0.00%)
After hours: 4:19PM EST
| Previous Close | 7.89 |
| Open | 7.92 |
| Bid | 7.71 x 1000 |
| Ask | 8.98 x 800 |
| Day's Range | 7.68 - 8.08 |
| 52 Week Range | 5.49 - 18.94 |
| Volume | 148,625 |
| Avg. Volume | 290,701 |
| Market Cap | 332.151M |
| Beta (3Y Monthly) | 0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.31 |
| Earnings Date | Feb 25, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.68 |
- MarketWatch
ProQR shares rises on FDA orphan drug designation
Shares of ProQR Therapeutics rose 10% in premarket trading after it said the Food and Drug Administration had granted an orphan-drug designation to QR-1123. The experimental therapy is being tested as a treatment for vision loss caused by autosomal dominant retinitis pigmentosa (adrp), a rare eye disease. "Our goal is to develop and actively advance a pipeline of programs that can treat inherited retinal diseases like adRP in a targeted manner," ProQR CEO Daniel de Boer said in a news release. ProQR stock is down 51% year-to-date, while the S&P 500 has gone up 24%.
- GlobeNewswire
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. ODD provides a special status for investigational drugs being developed for rare diseases.
- GlobeNewswire
ProQR to Present at Upcoming Scientific Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
- GlobeNewswire
ProQR to Present at Upcoming Investor Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
- Insider Monkey
Were Hedge Funds Right About Dumping ProQR Therapeutics NV (PRQR)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- Zacks
Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates
Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.
- Zacks
ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -9.38% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1.
- Zacks
Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
- Zacks
BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3
BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.
- Zacks
Will ProQR Therapeutics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor ProQR Therapeutics.
- GlobeNewswire
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
Citigroup Global Markets and Evercore ISI acted as joint bookrunners for the offering. Cantor Fitzgerald & Co. and JMP Securities acted as lead managers, with Chardan and Kempen acting as co-managers.
- Benzinga
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
- GlobeNewswire
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the pricing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 1,363,636 additional ordinary shares at the public offering price, less underwriting discounts and commissions.
- GlobeNewswire
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it intends to offer and sell $50,000,000 of its ordinary shares in an underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $7,500,000 of ordinary shares, on the same terms and conditions.
- GlobeNewswire
ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA) for sepofarsen for the treatment of Leber’s congenital amaurosis 10 (LCA10), the most common cause of blindness due to genetic disease in children.
- Benzinga
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...
- GlobeNewswire
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced positive top-line results from the PQ-110-001 study, a Phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported today that patients receiving sepofarsen had a clinically meaningful improvement in vision, and in some cases the patient’s vision improved to a level that could be deemed life changing. This is very encouraging for the LCA10 community and the Inherited Retinal Disease community as a whole,” said Stephen R. Russell, MD, Schrage Professor of Ophthalmology and Visual Sciences and Principal Investigator at the University of Iowa.
- GlobeNewswire
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will present and discuss top-line results from the Phase 1/2 study of sepofarsen on October 10, ahead of the American Academy of Ophthalmology's annual meeting to be held in San Francisco, CA, U.S. PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Two dose levels are being tested, 80 μg (160 μg loading dose) and 160 μg (320 μg loading dose).
- Zacks
ProQR Therapeutics Enters Oversold Territory
ProQR Therapeutics N.V. (PRQR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- GlobeNewswire
ProQR to Present at Two Investor Conferences in October
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
- Simply Wall St.
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Zacks
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
- GlobeNewswire
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-1123. QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. Fast Track designation is granted by the FDA to drugs in development for serious conditions with the potential to fulfill an unmet medical need.
- Zacks
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
